The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells

Stem Cells and Development

Volumn 19, Issue 10, 2010, Pages 1523-1533

  Yoon, Dong Suk ^a   Yoo, Je Hyun ^a,b   Kim, Yun Hee ^a   Paik, Seungil ^a   Han, Chang Dong ^a   Lee, Jin Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Hallym University Sacred Heart Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CELECOXIB; INTERLEUKIN 1BETA; MESSENGER RNA; NAPROXEN; OSTEOCALCIN; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ARTICLE; BONE CELL; BONE DEVELOPMENT; BONE MARROW; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; INHIBITION KINETICS; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; NAPROXEN; OSTEOGENESIS; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; YOUNG ADULT;

EID: 77957593126     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2009.0393     Document Type: Article

References (41)

1. Kaplan-Machlis B and BS Klostermeyer. (1999). The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 33:979-988.
2. Clemett D and KL Goa. (2001). Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 61(4):498.
3. Gray PA, TD Warner, I Vojnovic, P Del Soldato, A Parikh, GK Scadding and JA Mitchell. (2002). Effects of non-steroidal antiinflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol 137:1031-1038.
4. Botting R. (2000). Paracetamol-inhibitable COX-2. J Physiol Pharmacol 51(4 PART 1):609-618.
5. Bang UC, S Semb, C Nojgaard and F Bendtsen. (2008). Pharmacological approach to acute pancreatitis. World J Gastroenterol 14:2968-2976.
6. Okada Y, JA. Lorenzo, AM. Freeman, M Tomita, SG Morham, LG Raisz and CC Pilbeam. (2000). Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105:823-832.
7. Crofford LJ. (1997). COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 49:15-19.
8. Ferraz JG, KA Sharkey, BK Reuter, S Asfaha, AW Tigley, ML Brown, W McKnight and JL Wallace. (1997). Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage. Gastroenterology 113:195-204.
9. Funk CD, LB Funk, ME Kennedy, AS Pong and GA Fitzgerald. (1991). Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 5:2304-2312.
10. Chen QR, C Miyaura, S Higashi, M Murakami, I Kudo, S Saito, T Hiraide, Y Shibasaki and T Suda. (1997). Activation of cytosolic phospholipase A2 by platelet-derived growth factor is essential for cyclooxygenase-2-dependent prostaglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1. J Biol Chem 272:5952-5958.
11. Kawaguchi H, CC Pilbeam, G Gronowicz, C Abreu, BS Fletcher, HR Herschman, LG Raisz and MM Hurley. (1995). Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor. J Clin Invest 96:923-930.
12. Yamamoto K, T Arakawa, N Ueda and S Yamamoto. (1995). Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270:31315-31320.
13. Sato T, I Morita, K Sakaguchi, KI Nakahama, WL Smith, DL Dewitt and SI Murota. (1996). Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J Bone Miner Res 11:392-400.
14. Zhang X, SG Morham, R Langenbach, DA Young, L Xing, BF Boyce, EJ Puzas, RN Rosier, RJ O'Keefe, and EM Schwarz. (2001). Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res 16:660-670.
15. Tai H, C Miyaura, CC Pilbeam, T Tamura, Y Ohsugi, Y Koishihara, N Kubodera, H Kawaguchi, LG Raisz and T Suda. (1997). Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138:2372-2379.
16. Suponitzky, I and M Weinreb. (1998). Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol 156:51-57
17. Zhang X, EM Schwarz, DA Young, JE Puzas, RN Rosier and RJ O'Keefe. (2002). Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405-1415.
18. Simon AM, MB Manigrasso and JP O'Connor. (2002). Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17:963-976.
19. Goodman S, T Ma., M Trindade, T Ikenoue, I Matsuura, N Wong, N Fox, M Genovese, D Regula and RL Smith. (2002). COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 20:1164-1169.
20. Murnaghan M, G Li and DR Marsh. (2006). Nonsteroidal antiinflammatory drug-induced fracture nonunion: an inhibition of angiogenesis? J Bone Joint Surg Am 88 SUPPL. 3:140-147
21. Katori M, M Majima and Y Harada. (1998). Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflamm Res 47(SUPPL. 2):S107-S111.
22. Miller SC and SC Marks Jr. (1994). Effects of prostaglandins on the skeleton. Clin Plast Surg 21:393-400.
23. Norrdin RW, WS Jee and WB High. (1990). The role of prostaglandins in bone in vivo. Prostaglandins Leukot Essent Fatty Acids 41:139-149.
24. Long J, S Lewis, T Kuklo, Y Zhu and KD Riew. (2002). The effect of cyclooxygenase-2 inhibitors on spinal fusion. J Bone Joint Surg Am 84-A:1763-1768.
25. Reuben SS and EF Ekman. (2005). The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am 87:536-542.
26. Andersen T, FB Christensen, M Laursen, K Hoy ES Hansen and C Bünger,. (2001). Smoking as a predictor of negative outcome in lumbar spinal fusion. Spine 26:2623-2628.
27. Glassman SD, SM Rose, JR Dimar, RM Puno, MJ Campbell and JR Johnson. (1998). The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 23:834-838.
28. Premyslova M, H Chisaka, K Okamura and JR Challis. (2006). IL-lbeta treatment does not co-ordinately up-regulate mPGES-1 and COX-2 mRNA expression, but results in higher degree of cellular and intracellular co-localization of their immunoreactive proteins in human placenta trophoblast cells. Placenta 27:576-586.
29. Capone ML, S Tacconelli, L Di Francesco, A Sacchetti, MG Sciulli and P Patrignani. (2007). Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82:85-94.
30. Niederberger E, C Manderscheid, S Grösch, H, Schmidt, C Ehnert and G Geisslinger. (2004). Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68:341-350.
31. Murakami M, H Naraba, T Tanioka, N Semmyo, Y Nakatani, F Kojima, T Ikeda, M Fueki, A Ueno, S Oh and I Kudo. (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275:32783-32792.
32. Tanioka T, Y Nakatani, N Semmyo, M Murakami and I Kudo. (2000). Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275:32775-32782.
33. Forwood MR. (1996). Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11:1688-1693.
34. Okada Y, JA Lorenzo, AM Freeman, M Tomita, SG Morham, LG Raisz and CC Pilbeam. (2000). Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105:823-832.
35. Arikawa T, K Omura and I Morita. (2004). Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 200:400-406.
36. Weinreb M, D Shamir, M Machwate, GA Rodan, S Harada and S Keila. (2006). Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity. Prostaglandins Leukot Essent Fatty Acids 75:81-90.
37. Weinreb M, I Suponitzky and S Keila. (1997). Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 20:521-526.
38. Mengshol JA, MP Vincenti and CE Brinckerhoff. (2001). IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 29:4361-4372.
39. Inada M, Y Wang, MH Byrne, MU Rahman, C Miyaura, C Lopez-Otín, and SM Krane. (2004). Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 101:17192-17197
40. Behonick DJ, Z Xing, S Lieu, JM Buckley, JC Lotz, RS Marcucio, Z Werb, T Miclau and C Colnot. (2007). Role of matrix metalloproteinase 13 in both endochondral and intramembranous ossification during skeletal regeneration. PLoS ONE 2:e1150.
41. Nakase T, K Takaoka, K Masuhara, K Shimizu, H Yoshikawa and T Ochi. (1997). Interleukin-1 beta enhances and tumor necrosis factor-alpha inhibits bone morphogenetic proteins-induced alkaline phosphatase activity in MC3T3-E1 osteoblastic cells. Bone 21:17-21.